Raleigh Capital Management Inc. Viking Therapeutics, Inc. Transaction History
Raleigh Capital Management Inc.
- $229 Million
- Q2 2025
A detailed history of Raleigh Capital Management Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 159 shares of VKTX stock, worth $4,534. This represents 0.0% of its overall portfolio holdings.
Number of Shares
159Holding current value
$4,534% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
454Shares Held
68.3MCall Options Held
7.72MPut Options Held
3.31M-
Vanguard Group Inc Valley Forge, PA10.2MShares$290 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$172 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$108 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$92.6 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$89.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.19B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...